

## Datasheet: HCA261

**BATCH NUMBER 1807**

<b>Description:</b>	HUMAN ANTI PALIVIZUMAB
<b>Specificity:</b>	PALIVIZUMAB
<b>Other names:</b>	SYNAGIS®
<b>Format:</b>	Purified
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	AbD23967
<b>Isotype:</b>	HuCAL Fab monovalent
<b>Quantity:</b>	0.1 mg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

### Product Form

A monovalent human recombinant Fab (lambda light chain) selected from the HuCAL® phage display library, expressed in *E. coli*. The antibody is tagged with a DYKDDDDK tag and a HIS-tag (HHHHHH) at the C-terminus of the antibody heavy chain. This antibody is supplied as a liquid.

### Preparation

Metal chelate affinity chromatography

### Buffer Solution

Phosphate buffered saline

### Preservative Stabilisers

0.01% Thiomersal

### Approx. Protein Concentrations

Antibody concentration 0.5 mg/ml

### Immunogen

Palivizumab

**Specificity** **Human anti Palivizumab, clone AbD23967**, is a paratope specific, high affinity, anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug palivizumab and inhibits it binding to its target. The antibody can be used to measure the levels of palivizumab and biosimilar products in bioanalytical assays.

Our anti palivizumab antibodies can be used to develop a pharmacokinetic (PK) bridging assay to measure free drug. This antibody, in monovalent Fab format, is recommended as the capture antibody, paired with the antibody in full immunoglobulin (Ig) format, clone AbD23967\_hIgG1 ([HCA262](#)), as the detection antibody. The antibody in Ig format can also be used to develop and calibrate immune response assays to measure the anti-drug antibody (ADA) response in patient sera.

Palivizumab (Synagis®) is a humanized mouse monoclonal antibody (IgG1/kappa) specific to an epitope of the F protein of respiratory syncytial virus (RSV). It binds the antigenic site A, a highly conserved region on the RSV F protein between amino acids 258 and 275. RSV is known to cause infections of the lower respiratory tract in a clear seasonal pattern during the winter months. Administration of the drug is recommended for premature infants (under 35 weeks gestation), infants with certain congenital heart defects (CHD) or bronchopulmonary dysplasia (BPD) throughout the duration of the RSV season. It is approved by the FDA and EMA as a treatment for respiratory tract infection caused by RSV.

[View a summary of all anti-palivizumab antibodies](#)

---

**Affinity** The monovalent intrinsic affinity of this antibody was measured as  $K_D = 1.5$  nM by real time, label free molecular interaction analysis on immobilized palivizumab.

---

**ELISA** This product may be used in direct or indirect ELISA and in a PK bridging ELISA as a capture antibody together with the same antibody or [HCA262P](#) as the detection reagent. Protocol: [PK bridging ELISA to measure free drug](#)

---

**Storage** Store at +4°C or at -20°C if preferred.  
Storage in frost-free freezers is not recommended.  
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.

---

**Guarantee** 12 months from date of despatch

---

**Acknowledgements** Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.  
His-tag is a registered trademark of EMD Biosciences.

---

**Health And Safety Information** Material Safety Datasheet documentation #10094 available at: <https://www.bio-rad-antibodies.com/SDS/HCA261>  
10094

---

**Licensed Use** For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

---

**Regulatory** For research purposes only

---

**Technical Advice** Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the [HuCAL Antibodies Technical Manual](#)

---

## Related Products

### Recommended Secondary Antibodies

Rat Anti Synthetic Peptide DYKDDDDK TAG (MCA4764...) [HRP](#)

Mouse Anti Synthetic Peptide HISTIDINE TAG (MCA5995...) [HRP](#)

### Recommended Useful Reagents

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[HUMAN ANTI PALIVIZUMAB \(HCA262\)](#)

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](https://bio-rad-antibodies.com/datasheets)

'M371693:200612'

**Printed on 25 Mar 2023**

---

© 2023 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)